Allergan ruling casts doubt on tribal patent strategy
(Reuters) - A U.S. judge ’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Judge in Texas Invalidates Allergan Patents on Restasis U.S. Judge in Texas Invalidates Allergan Patents on Restasis
A U.S. judge invalidated patents on Allergan Plc ' s dry eye medicine Restasis on the grounds that the patents cover obvious ideas, a decision that drove the pharmaceutical company ' s shares down more than 6%.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 17, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Mylan: Allergan ’ s legal move with tribe reveals “ duplicitousness ” towards patent system
Allergan (NYSE:AGN) was dealt a major blow yesterday after a Texas judge ruled that claims to a number of patents for its dry eye drug, Restasis, were invalid due to obviousness. The ruling opens the door for generic versions of the drug that accounted for nearly 10% of Allergan’s revenue last year. The decision came in a suit involving generic drugmakers like Mylan (NSDQ:MYL), which celebrated the ruling as a push back against Allergan’s recent move to transfer its Restasis patents to a Native American tribe. Get the full story at our sister site, Drug Delivery Business News. The post Mylan: Allergan’s legal ...
Source: Mass Device - October 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news

Patents For Restasis Are Invalidated, Opening Door to Generics
The ruling, by a federal judge in Texas, is a setback for Allergan, which had transferred the patents to a Mohawk tribe in order to protect them. (Source: NYT Health)
Source: NYT Health - October 16, 2017 Category: Consumer Health News Authors: KATIE THOMAS Tags: Inventions and Patents Drugs (Pharmaceuticals) Generic Brands and Products Allergan Inc Patent and Trademark Office (US) Source Type: news

Texas judge rules Allergan ’s Restasis patents invalid
U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today. The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA). Get the full story at our sister site, Drug Delivery Business News. The post Texas judge rules Allergan’s Restasis patents invalid appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Teva Pharmaceuticals Source Type: news

U.S. judge in Texas invalidates Allergan patents on Restasis
(Reuters) - Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

MassDevice.com +5 | The top 5 medtech stories for October 13, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. 10 tips for selecting and managing a medtech development partner There many things to consider when searching for and interacting with a product development firm – and the stakes are high! Most early-stage medical device comp...
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Allergan settles Restasis patent challenge after moving patents to Native American tribe
Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis. InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in federal court. Get the full story at our sister site, Drug Delivery Business News. The post Allergan settles Restasis patent challenge after moving patents to Native American tribe appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Akorn Allergan Inc. innopharma Mylan Teva Pharmaceuticals Source Type: news

Allergan settles with one of four companies contesting Restasis patent
(Reuters) - Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute
Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Mylan says Allergan misusing tribal sovereignty in patent dispute
NEW YORK (Reuters) - Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis. (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan pays Mohawk Tribe to protect patents from challenges
(Reuters) - Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. (Source: Reuters: Health)
Source: Reuters: Health - September 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Shire applies for European approval of potential blockbuster eye drop
One of the state ’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016 . It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2017 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Gengraf Capsules (Cyclosporine Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 11, 2017 Category: Drugs & Pharmacology Source Type: news